Hide metadata

dc.date.accessioned2023-07-12T08:44:55Z
dc.date.available2023-07-12T08:44:55Z
dc.date.created2023-04-13T18:09:13Z
dc.date.issued2023
dc.identifier.citationPapotti, Bianca Opstad, Trine Baur Åkra, Sissel Tønnessen, Theis Braathen, Bjørn Hansen, Charlotte Holst Arnesen, Harald Solheim, Svein Seljeflot, Ingebjørg Ronda, Nicoletta . Macrophage polarization markers in subcutaneous, pericardial, and epicardial adipose tissue are altered in patients with coronary heart disease. Frontiers in Cardiovascular Medicine. 2023, 10
dc.identifier.urihttp://hdl.handle.net/10852/102725
dc.description.abstractBackground: Epicardial and pericardial adipose tissue (EAT and PAT) surround and protect the heart, with EAT directly sharing the microcirculation with the myocardium, possibly presenting a distinct macrophage phenotype that might affect the inflammatory environment in coronary heart disease (CHD). This study aims to investigate the expression of genes in different AT compartments driving the polarization of AT macrophages toward an anti-inflammatory (L-Galectin 9; CD206) or pro-inflammatory (NOS2) phenotype. Methods: EAT, PAT, and subcutaneous (SAT) biopsies were collected from 52 CHD patients undergoing coronary artery bypass grafting, and from 22 CTRLs undergoing aortic valve replacement. L-Galectin9 (L-Gal9), CD206, and NOS2 AT gene expression and circulating levels were analyzed through RT-PCR and ELISA, respectively. Results: L-Gal9, CD206, and NOS2 gene expression was similar in all AT compartments in CHD and CTRLs, as were also L-Gal9 and CD206 circulating levels, while NOS2 serum levels were higher in CHD (p = 0.012 vs. CTRLs). In CTRLs, NOS2 expression was lower in EAT vs. SAT (p = 0.007), while in CHD patients CD206 expression was lower in both SAT and EAT as compared to PAT (p = 0.003, p = 0.006, respectively), suggestive of a possible macrophage reprogramming toward a pro-inflammatory phenotype in EAT. In CHD patients, NOS2 expression in SAT correlated to that in PAT and EAT (p = 0.007, both), CD206 expression correlated positively to L-Gal9 (p < 0.001) only in EAT, and CD206 expression associated with that of macrophage identifying markers in all AT compartments (p < 0.001, all). In CHD patients, subjects with LDL-C above 1.8 mmol/L showed significantly higher NOS2 expression in PAT and EAT as compared to subjects with LDL-C levels below (p < 0.05), possibly reflecting increased cardiac AT pro-inflammatory activation. In SAT and PAT, CD206 expression associated with BMI in both CHD and CTRLs (p < 0.05, all), and with L-Gal9 in EAT, however only in CTRLs (p = 0.002). Conclusion: CHD seems to be accompanied by an altered cardiac, and especially epicardial AT macrophage polarization. This may represent an important pathophysiological mechanism and a promising field of therapy targeting the excessive AT inflammation, in need of further investigation.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleMacrophage polarization markers in subcutaneous, pericardial, and epicardial adipose tissue are altered in patients with coronary heart disease
dc.title.alternativeENEngelskEnglishMacrophage polarization markers in subcutaneous, pericardial, and epicardial adipose tissue are altered in patients with coronary heart disease
dc.typeJournal article
dc.creator.authorPapotti, Bianca
dc.creator.authorOpstad, Trine Baur
dc.creator.authorÅkra, Sissel
dc.creator.authorTønnessen, Theis
dc.creator.authorBraathen, Bjørn
dc.creator.authorHansen, Charlotte Holst
dc.creator.authorArnesen, Harald
dc.creator.authorSolheim, Svein
dc.creator.authorSeljeflot, Ingebjørg
dc.creator.authorRonda, Nicoletta
cristin.unitcode185,53,11,10
cristin.unitnameHjertemedisinsk avdeling
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2140706
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Cardiovascular Medicine&rft.volume=10&rft.spage=&rft.date=2023
dc.identifier.jtitleFrontiers in Cardiovascular Medicine
dc.identifier.volume10
dc.identifier.pagecount0
dc.identifier.doihttps://doi.org/10.3389/fcvm.2023.1055069
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2297-055X
dc.type.versionPublishedVersion
cristin.articleid1055069


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International